Stock Region Penny Picks
Movers, Shakers, and Heartbreakers
Movers, Shakers, and Heartbreakers
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
The following is not financial advice. All content is for informational and entertainment purposes only. The stock market is a wild ride, and you should always do your own research before making any investment decisions. We are not financial advisors, and any opinions expressed here are just that—opinions.
What a day it’s been. The market never sleeps, and neither do the press releases. We saw some truly interesting moves yesterday, from major contract wins to some gut-wrenching FDA news. Let’s break down what caught my eye and what it could mean for our watchlists.
The Good, The Bad, and The Complicated
Here’s a rundown of the tickers that made waves:
$SWVL (Swvl Holdings Corp.)
Swvl just keeps hitting home runs in the UAE. They’ve locked in a new five-year contract worth up to $5.5 million. This comes after they grew their business there by nearly 5x in 2025. Honestly, this isn’t surprising. The UAE is their fastest-growing market, and this contract just cements their dominance. It’s a solid vote of confidence and shows their model is working. Definitely one to watch for continued momentum.$SKYE (Skye Bioscience, Inc.)
Positive clinical trial news always gets my attention. Skye announced positive interim results from their Phase 2a study for Nimacimab, especially when used with semaglutide. This is a big deal in the metabolic disease space. While it’s still early days (interim results are just a snapshot), it’s a very encouraging sign. Positive data can be a powerful catalyst, so I’m keeping a close eye on SKYE.$AQST (Aquestive Therapeutics, Inc.)
And here’s the gut punch. Aquestive received a Complete Response Letter (CRL) from the FDA for their epinephrine film, Anaphylm™. A CRL is never what you want to see. It means the FDA isn’t ready to approve the drug and needs more information. This is a huge setback for the company and, frankly, a disappointment for anyone hoping for an alternative to EpiPens. The stock will likely feel this pain. It’s a harsh reminder of the risks in biotech investing.$SMTK (Smartkem, Inc.)
From tech to… nuclear-grade graphite? Smartkem signed a Letter of Intent to expand into this highly specialized materials sector. This is a pivot, and pivots can be risky, but they can also be brilliant. Nuclear-grade graphite is a critical material, and this move could open up a whole new, high-margin market for SMTK. It’s an unusual but intriguing development that shows management is thinking outside the box.$FUSE (Fusemachines Inc.)
AI partnerships are the name of the game right now. Fusemachines is teaming up with ModulAIre, an IBM Platinum Partner. This strategic move aims to deliver enterprise-level AI solutions. It’s a smart play. By partnering up, Fusemachines gets access to a wider client base and IBM’s powerful ecosystem. This could be a significant driver for their growth as more big companies look to adopt AI.$FATN (FatPipe Inc.)
Now for some earnings love! FatPipe reported a fantastic quarter. Revenues are up 30%, their monthly recurring revenue (MRR) jumped 48% year-over-year, and they are now cash flow positive. These are the kinds of numbers we love to see. Strong, consistent growth and profitability are a beautiful combination. It shows the business is healthy and scaling effectively.$FIEE (FiEE, Inc.)
FiEE gave us a sneak peek at their Q4 and full-year 2025 results. Releasing preliminary results can be a way to manage expectations or signal strong performance ahead of the official report. We’ll have to wait for the full details to get the complete picture, but it’s enough to put them on the radar. What they’ve shared so far will be closely scrutinized by investors.
That’s the scoop for today. We saw some wins, a tough loss, and a few strategic moves that could pay off down the road. It’s a perfect illustration of why we stay diversified and always, always do our homework.
Stay sharp out there!
Final Disclaimer: Investing carries risk. The value of your investments can go down as well as up. Any stock tickers mentioned in this newsletter are for discussion purposes only and do not constitute a recommendation to buy or sell. Please consult with a licensed financial professional before making any investment decisions. We may or may not hold positions in the stocks mentioned.